The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Forecasted Market Size Figures For The Chemotherapy-Induced Nausea and Vomiting (CINV) Market In 2026 And 2030?
The market for chemotherapy-induced nausea and vomiting (cinv) has experienced substantial growth in recent years. This market is expected to expand from $3.13 billion in 2025 to $3.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.0%. Historically, this growth can be attributed to the increased application of highly emetogenic chemotherapy, a growing understanding of treatment side effects, the accessibility of advanced antiemetic drugs, the expansion of oncology treatment programs, and refined clinical guidelines for cinv management.
The market size for chemotherapy-induced nausea and vomiting (cinv) is projected to experience robust expansion over the next few years. It is expected to reach $4.57 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.0%. This anticipated growth can be attributed to several factors, including the increasing demand for advanced antiemetics, the rising adoption of personalized antiemetic therapies, the expansion of outpatient chemotherapy services, a heightened focus on adherence to treatment protocols, and advancements in sustained-release formulations. Significant trends during the forecast period are expected to include the wider adoption of combination antiemetic regimens, increased utilization of long-acting cinv drugs, an evolving focus on patient-centric treatment approaches, the broadening of preventive cinv management protocols, and an enhanced emphasis on quality-of-life outcomes.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp
What Key Growth Drivers Are Influencing The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
The expanding incidence of cancer is projected to fuel the chemotherapy-induced nausea and vomiting (CINV) market in the future. Cancer describes a condition where certain bodily cells proliferate uncontrollably and metastasize to other areas. With the ongoing rise in cancer diagnoses, there is an enhanced drive to create more potent and focused anti-emetic treatments to mitigate CINV, a challenging adverse effect of chemotherapy. This increased emphasis on CINV management has fostered progress in comprehending its fundamental mechanisms and in pioneering new therapies. For example, in January 2023, the American Cancer Society (ACS), a US-based volunteer health organization dedicated to eradicating cancer, estimated that the United States would see 1.9 million new cancer cases (around 5,370 cases daily) and 609,820 cancer deaths (approximately 1,670 deaths each day) in 2023. Consequently, the rising prevalence of cancer is set to propel the chemotherapy-induced nausea and vomiting (CINV) market.
What Key Segment Areas Are Included In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Assessment?
The chemotherapy-induced nausea and vomiting (cinv) market covered in this report is segmented –
1) By Form: Injectables, Oral, Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoids, Other Drug Classes
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC), Moderately Emetogenic Chemotherapy (MEC), Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals, Cancer Research Institute, Retail Pharmacies, Online Pharmacies, Drug Stores
5) By Application: Gynecology, Urology, Gastrointestinal Surgery, Other Applications
Subsegments:
1) By Injectables: Intravenous (IV) Solutions, Intramuscular (IM) Injections
2) By Oral: Tablets, Capsules, Liquid Formulations
3) By Transdermal Patches: Fentanyl Patches, Scopolamine Patches
Which Trends Are Affecting The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Framework?
Key entities active within the chemotherapy-induced nausea and vomiting (CINV) market are focusing on novel product innovations, including fixed intravenous antiemetics, to secure a competitive edge. This type of antiemetic involves a pre-set quantity of medicine delivered intravenously to manage or avert nausea and vomiting, frequently employed in contexts like chemotherapy or following surgical procedures. For example, in January 2023, Glenmark Pharmaceuticals Limited, an India-based producer of pharmaceuticals, generics, and over-the-counter (OTC) products, launched AKYNZEO I.V. in India, marking it as the initial fixed intravenous antiemetic combination specifically formulated to prevent chemotherapy-induced nausea and vomiting (CINV). The product integrates netupitant and palonosetron, effectively addressing both the acute and delayed manifestations of nausea and vomiting. It provides the benefit of single-dose administration, contributes to higher complete response rates, and elevates the quality of life for individuals battling cancer. Clinical research has indicated its distinct advantage for patients receiving highly emetogenic chemotherapy.
Which Companies Are Influencing The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.
Access The Complete Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report:
Which Region Leads The Chemotherapy-Induced Nausea and Vomiting (CINV) Market By Size?
North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2025. The regions covered in the chemotherapy-induced nausea and vomiting (cinv) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp
Browse Through More Reports Similar to the Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2026, By The Business Research Company
Myeloproliferative Disorders Drugs Global Market Report 2026
Chemotherapy Induced Anemia Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
Chemotherapy Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model